Better Health for All

No specific, concrete data points were found across the provided articles to assess HCM.US against any of the 'Better Health for All' KPIs.

All articles explicitly state that no relevant data, quantitative metrics, or specific details are available for extraction.

Fair Money & Economic Opportunity

HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics.

The ethical value 'Fair Money & Economic Opportunity' assesses financial institutions and their provision of financial services such as lending, insurance, and wealth building. None of the provided articles contain evidence that HUTCHMED operates in the financial services sector or offers any financial products to consumers. Therefore, there is no relevant data to score any of the KPIs under this value.

Fair Pay & Worker Respect

HUTCHMED reported a Total Recordable Injury Rate (TRIR) of 0.28 cases per 200,000 hours worked in 2024, with zero work-related fatalities over the past three years (2021-2023).

The company's 2023 employee engagement survey achieved an overall score of 83/100, exceeding the pharmaceutical industry benchmark by 9 points, with a 96% response rate. In 2023, the voluntary employee turnover rate was 19.7%. The company states that close to 100% of its staff work on a full-time basis. All employees receive comprehensive benefit plans, including medical and social insurance, housing allowances, and retirement schemes. In 2024, the company maintained a 100% training rate for all employees on the Code of Ethics and reported no incidents of human rights violations. The female representation in senior management was 38.1% in 2024, and the overall workforce gender ratio was 46% male to 54% female.

Fair Trade & Ethical Sourcing

The company reported zero incidents of human rights violations in 2022 and 2024, and no reported cases of non-compliance related to child and forced labor in 2021.

It has established and enforced robust systems and controls to eliminate forced labor, prison labor, bonded labor, slavery, human trafficking, or employment below the legal minimum age. A comprehensive traceability program is in place, incorporating serialized barcodes on product carton boxes for tracking and verification throughout the supply chain, but there is no explicit data on the percentage of suppliers mapped beyond Tier 1. All suppliers are required to adhere to the company’s fundamental principles and policies, including the Code of Ethics for Business Partners, Human Rights Policy, and Anti-Bribery and Anti-Corruption laws, but the percentage of contracts with enforceable ethical-sourcing clauses is not specified.

Kind to Animals

The company's animal facility maintained accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) in 2024.

Its clinical research organizations also received AAALAC approval. Additionally, the animal facility obtained and passed annual and five-year reviews for its laboratory animal use license from the Science and Technology Commission of Shanghai Municipality (STCSM). In 2024, 100% of Tier I suppliers participated in either the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs. The company's animal testing policy incorporates the 3R principles (Replacement, Reduction, Refinement) and prohibits discretionary testing, requiring high-level sign-off for exceptions. In 2024, a total of 10,239 animals were used in internal research activities and 599 animals in external research activities, representing a 20% reduction compared to the previous year. In 2023, 11,940 animals were used in internal research and 1,618 in external research.

Planet-Friendly Business

HUTCHMED has set a net-zero target for 2050.

The company has fully adopted TCFD recommendations, including peer-reviewed scenario analysis, and integrates climate risk into its Enterprise Risk Management. It conducts comprehensive climate scenario analysis, including 1.5°C, 2°C, and 3°C+ pathways, with strategic planning explicitly linked to these scenarios and good disclosure in annual reports. The company conducted a biodiversity risk assessment and established a Biodiversity Policy. No major environmental compliance violations were reported.

Respect for Cultures & Communities

In 2023, 100% of new hires in Hong Kong and mainland China were from local communities.

The company supported a local village school in Ji'an City, Jiangxi Province, with educational resources, and through donations of SULANDA® (surufatinib) and a treatment subsidy program for TAZVERIK® (tazemetostat), reduced patient treatment costs by an estimated US$4.7 million. HUTCHMED also received the "Caring Company" award from the Hong Kong Council of Social Service for the third consecutive year.

Zero Waste & Sustainable Products

In 2023, the company recycled 5.728 tons of waste (4.278 tons of paper, 1.105 tons of plastic, and 0.345 tons of metals) out of a total of 174 tons of hazardous and non-hazardous waste generated, resulting in a waste diversion rate of 3.29%.

The company generated 106 tons of hazardous waste in 2023, uses external contractors for collection, treatment, and disposal, stores hazardous materials in appropriate containers, and inspects waste facilities. No waste disposal violations or citations were reported in the past three years. The company mentions a commitment to long-term waste reduction but does not provide specific targets or timelines. It has a Code of Ethics for Business Partners, expecting suppliers to meet high standards, with compliance monitored through engagement, ethical audits, and improvement programs for all tier-1 suppliers.